NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases.

NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to initiation of phase 3 clinical trials of its portfolio of therapeutic candidates. These first in class molecules have been developed from NovaBiotics’ two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.